Acenocoumarol
- Generic Name
- Acenocoumarol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H15NO6
- CAS Number
- 152-72-7
- Unique Ingredient Identifier
- I6WP63U32H
- Background
Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation. Hematocrit, hemoglobin, international normalized ratio and liver panel should be monitored. Pa...
- Indication
For the treatment and prevention of thromboembolic diseases. More specifically, it is indicated for the prevention of cerebral embolism, deep vein thrombosis, pulmonary embolism, thromboembolism in infarction and transient ischemic attacks. It is used for the treatment of deep vein thrombosis and myocardial infarction.
- Associated Conditions
- Coronary Occlusions, Pulmonary Embolism, Systemic Embolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
- Associated Therapies
- -
Start or STop Anticoagulants Randomised Trial (SoSTART)
- Conditions
- Interventions
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 203
- Registration Number
- NCT03153150
- Locations
- 🇬🇧
Frimley Park Hospital, Frimley, United Kingdom
🇬🇧Gloucestershire Royal Hospital, Gloucester, United Kingdom
🇬🇧Pinderfields Hospital, Wakefield, United Kingdom
Rivaroxaban for Patients With Antiphospholipid Syndrome
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2018-05-11
- Target Recruit Count
- 190
- Registration Number
- NCT02926170
- Locations
- 🇪🇸
Vall d'Hebron University Hospital, Barcelona, Spain
Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC)
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Semmelweis University Heart and Vascular Center
- Target Recruit Count
- 200
- Registration Number
- NCT02826200
- Locations
- 🇭🇺
Heart and Vascular Center, Semmelweis University, Budapest, Hungary
Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)
- Conditions
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Hospital Mutua de Terrassa
- Target Recruit Count
- 500
- Registration Number
- NCT02742480
- Locations
- 🇪🇸
Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
- Conditions
- Interventions
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT01851824
Tinzaparin in the Treatment of the Acute Pulmonary Embolism
- First Posted Date
- 2008-07-08
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Complejo Hospitalario Xeral-Calde
- Target Recruit Count
- 102
- Registration Number
- NCT00711308
- Locations
- 🇪🇸
Pneumology Service. Hospital do Meixoeiro, Vigo, Pontevedra, Spain
🇪🇸Pneumology Service. Hospital Clínico, Santiago de Compostela, A Coruña, Spain
🇪🇸Pneumology Service. Hospital Xeral Cies, Vigo, Pontevedra, Spain
Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2008-06-03
- Lead Sponsor
- Hospital Universitari de Bellvitge
- Target Recruit Count
- 241
- Registration Number
- NCT00689520
- Locations
- 🇪🇸
Vascular surgery service. Hospital Creu Roja de l'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Department of Vascular Surgery. Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers
- Conditions
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2008-03-26
- Lead Sponsor
- Maastricht University
- Target Recruit Count
- 20
- Registration Number
- NCT00512928
- Locations
- 🇳🇱
Maastricht University, Maastricht, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.